130 related articles for article (PubMed ID: 11245931)
1. Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease.
Hurley MJ; Mash DC; Jenner P
Brain Res Mol Brain Res; 2001 Mar; 87(2):271-9. PubMed ID: 11245931
[TBL] [Abstract][Full Text] [Related]
2. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain.
Hurley MJ; Mash DC; Jenner P
J Neural Transm (Vienna); 2003 Nov; 110(11):1279-88. PubMed ID: 14628192
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A(2A) receptor mRNA expression in Parkinson's disease.
Hurley MJ; Mash DC; Jenner P
Neurosci Lett; 2000 Sep; 291(1):54-8. PubMed ID: 10962152
[TBL] [Abstract][Full Text] [Related]
4. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Svenningsson P; Gunne L; Andren PE
Neuroscience; 2000; 99(3):457-68. PubMed ID: 11029538
[TBL] [Abstract][Full Text] [Related]
5. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease.
Anichtchik OV; Peitsaro N; Rinne JO; Kalimo H; Panula P
Neurobiol Dis; 2001 Aug; 8(4):707-16. PubMed ID: 11493035
[TBL] [Abstract][Full Text] [Related]
6. Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390.
Yu J; Coirini H; Källström L; Wiesel FA; Johnson AE
Synapse; 1998 Sep; 30(1):38-48. PubMed ID: 9704879
[TBL] [Abstract][Full Text] [Related]
7. Distribution of D1 and D2 dopamine receptors in the basal ganglia of the cat determined by quantitative autoradiography.
Beckstead RM; Wooten GF; Trugman JM
J Comp Neurol; 1988 Feb; 268(1):131-45. PubMed ID: 2964456
[TBL] [Abstract][Full Text] [Related]
8. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D-1 receptors in the parkinsonian brain.
Rinne JO; Rinne JK; Laakso K; Lönnberg P; Rinne UK
Brain Res; 1985 Dec; 359(1-2):306-10. PubMed ID: 2934111
[TBL] [Abstract][Full Text] [Related]
10. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
Hurley MJ; Mash DC; Jenner P
Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
[TBL] [Abstract][Full Text] [Related]
11. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
Lastres-Becker I; Cebeira M; de Ceballos ML; Zeng BY; Jenner P; Ramos JA; Fernández-Ruiz JJ
Eur J Neurosci; 2001 Dec; 14(11):1827-32. PubMed ID: 11860478
[TBL] [Abstract][Full Text] [Related]
12. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
13. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
[TBL] [Abstract][Full Text] [Related]
14. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
Glass M; Dragunow M; Faull RL
Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
[TBL] [Abstract][Full Text] [Related]
15. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease.
Hurley MJ; Stubbs CM; Jenner P; Marsden CD
Neurosci Lett; 1996 Aug; 214(2-3):75-8. PubMed ID: 8878087
[TBL] [Abstract][Full Text] [Related]
16. Quantitative autoradiography reveals regionally selective changes in dopamine D1 and D2 receptor binding in the genetically dystonic hamster.
Nobrega JN; Richter A; Tozman N; Jiwa D; Löscher W
Neuroscience; 1996 Apr; 71(4):927-37. PubMed ID: 8684623
[TBL] [Abstract][Full Text] [Related]
17. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients.
Fernandez A; de Ceballos ML; Jenner P; Marsden CD
Neuroscience; 1994 Jul; 61(1):73-9. PubMed ID: 7969897
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
19. Association of dopamine D1 and D2 receptors with specific cellular elements in the basal ganglia of the cat: the uneven topography of dopamine receptors in the striatum is determined by intrinsic striatal cells, not nigrostriatal axons.
Beckstead RM
Neuroscience; 1988 Dec; 27(3):851-63. PubMed ID: 3150855
[TBL] [Abstract][Full Text] [Related]
20. Blockade of dopamine D2, but not of D1 receptors in the rat globus pallidus induced Fos-like immunoreactivity in the caudate-putamen, substantia nigra and entopeduncular nucleus.
Hauber W; Lutz S
Neurosci Lett; 1999 Aug; 271(2):73-6. PubMed ID: 10477105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
